CAR T cell therapy market is estimated to grow at a CAGR of nearly 48% during the forecast period. The major factors contributing to the growth of the market include a significant prevalence of cancer across the globe and rising FDA approvals for cell and gene therapy. As per the World Health Organization (WHO), the global cancer burden is estimated to have risen to 18.1 million new cases and 9.6 million deaths in 2018. There were 43.8 million persons living with cancer in 2018 who were diagnosed within the last 5 years. This rising prevalence of cancer is attributing to the development of CAR T cell therapy. It is a form of immunotherapy that utilizes specially altered T cells, a part of the immune system to attack cancer.
There are currently two CAR T cell therapies approved for the treatment of cancer, which includes Yescarta and Kymriah. Yescarta was approved by the US FDA in October 2017, for the treatment of diffuse large B-cell lymphoma (DLBCL). Kymriah was approved by the US FDA in May 2018, for the treatment of adults with certain kinds of non-Hodgkin lymphoma. Kymriah is also approved for the treatment of children and young adults with leukemia. In clinical trials, more than 80% of young adults and children treated with Kymriah achieved cancer remission.
Early results of CAR T-cell therapy to treat lymphoma and other blood cancers are promising. Multiple patients with failed standard treatments or whose blood cancers returned achieved complete success with CAR T cell therapy. As a result, the US FDA is focusing on the approvals of cell and gene therapies. Several CAR T cell therapies are in clinical phases for the treatment of breast cancer, colorectal cancer and blood cancer. The launch of these novel therapies will likely offer an opportunity for the growth of the market.
To Request a Sample of our Report on CAR T cell Therapy Market: https://www.omrglobal.com/request-sample/car-t-cell-therapy-market
CAR T cell Therapy Market Segmentation
By Application
- Non-Hodgkin Lymphoma
- Acute Lymphocytic Leukemia
- Others (Multiple Myeloma, Hodgkin Lymphoma, and Breast Cancer)
By Target Antigen
- CD19
- CD22
- Others (CD123, CD33, and BCMA)
A full report of CAR T Cell Therapy Market is available at: https://www.omrglobal.com/industry-reports/car-t-cell-therapy-market
CAR T Cell Therapy Market– Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- Amgen Inc.
- Autolus Therapeutics plc
- bluebird bio, Inc.
- Bristol-Myers Squibb Co.
- CARsgen Therapeutics Co., Ltd.
- Cellectis SA
- Celyad SA
- Gilead Sciences, Inc.
- Intellia Therapeutics, Inc.
- Janssen Global Services, LLC (a Subsidiary of Johnson & Johnson)
- LesLaboratoiresServier, SAS
- Mustang Bio
- Nanjing Legend Biotechnology Co., Ltd.
- Noile-Immune Biotech Inc.
Reasons to Buy From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
